Tumors have elaborate suppressive mechanisms against host immune system to enhance their survival. We believe that ovarian tumors highly express a protein called CD73 that limits anti-tumor immune response to promote tumor growth. Our recent research demonstrates that CD73 may serve as an emerging immune target for ovarian cancer treatment. In this proposal, we will evaluate the efficacy of CD73 blockade with a FDA-approved drug as a novel means to enhance ovarian cancer immunotherapy. We hope open the door for the rapid translation of these preclinical findings into the clinic for effective ovarian cancer treatment.
|Effective start/end date||4/1/14 → 3/31/15|
- Marsha Rivkin Center for Ovarian Cancer Research (Awarded 3/11/14)